Please login to the form below

Not currently logged in
Email:
Password:

Boston Biomedical appoints commercial head

Patricia Andrews joins from Incyte Corporation

Boston Biomedical has named Pfizer veteran Patricia Andrews as chief commercial officer.

Andrews joins Boston Biomedical – a subsidiary of Japanese firm Dainippon Sumitomo Pharma – to bulk up its commercialisation efforts as lead drug candidate BBI608 nears phase III completion for use in metastatic colorectal cancer.

She previously spent 17 years at Pfizer, rising to VP and general manager of US oncology, before joining from oncology/inflammation-focused Incyte Corporation where she served as executive VP and chief commercial officer.

At Incyte, she established the company's commercial operations and successfully launched Jakafi (ruxolitinib) for myelofibrosis as part of a collaboration with Novartis.

Andrews is expected to perform a similar role at Boston, which has so far been focused on research.

"I am very excited about this opportunity and look forward to building a world-class commercial oncology team at Boston Biomedical," she said.

21st November 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics